---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-054480"
form_type: "8-K"
ticker: "TTRX"
cik: "0002023016"
company_name: "Turn Therapeutics Inc."
filed_at: "2026-05-11T20:10:24+00:00"
generated_at: "2026-05-11T22:20:35.366889+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Turn Therapeutics Q1 net loss $971K; Phase 2 AD trial on track, topline mid-2026

## Summary
- Cash and equivalents $11.2M as of March 31, 2026, up from $5.1M at Dec 31, 2025.
- Net loss $970,972 ($0.03 basic EPS) vs $328,547 ($0.01) in Q1 2025.
- G&A expenses $1.1M, R&D $109K; total op expenses $1.25M.
- Avenue Capital facility provides up to $25M; initial $7M funded March 24, 2026; $18M available on milestones.
- Phase 2 trial of GX-03 for moderate-to-severe atopic dermatitis; interim analysis Q2 2026, topline mid-2026.

## SEC filing metadata
- accession: 0001213900-26-054480
- form_type: 8-K
- ticker: TTRX
- cik: 0002023016
- company_name: Turn Therapeutics Inc.
- filed_at: 2026-05-11T20:10:24+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2023016/000121390026054480/0001213900-26-054480-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2023016/000121390026054480/ea0289856-8k_turn.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-054480
- JSON: https://secwatch.observer/filing/0001213900-26-054480.json
- Plain text: https://secwatch.observer/filing/0001213900-26-054480.txt

## Key facts
- Earnings Releases
  Turn Therapeutics Inc. reported three months ended March 31, 2026 results: net income $ (970,972 ), EPS $ (0.03 ).
  - Period: three months ended March 31, 2026
  - Net income: $ (970,972 )
  - EPS: $ (0.03 )
  - Result: reported results
  source text: Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunological therapies for dermatologic conditions, today reported financial results for the three months ended March 31, 2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/2023016/000121390026054480/0001213900-26-054480-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.